Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza Virus Vaccine USP Quadrivalent, 2012 2013 Formulation · 1 trial · 1 indication
Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay.
Antibodies against the influenza vaccine virus antigens were measured using a Hemagglutination-inhibition (HAI) assay. Seroconversion was defined as titer\< 10 (1/dil) on Day 0 and post injection titer ≥ 40 (1/dil) on Day 28, or titer ≥10 (1/dil) on Day 0 and a ≥4 fold increase in titer (1/dil) on Day 28).
| Arm | Type | Description |
|---|---|---|
| QIV ID Vaccine Group | EXPERIMENTAL | Participants will receive the intradermal quadrivalent influenza vaccine |
| TIV ID1 Vaccine Group | ACTIVE_COMPARATOR | Participants will receive the trivalent influenza vaccine containing the B strain from the primary (Yamagata) lineage |
| TIV ID2 Group | ACTIVE_COMPARATOR | Participants will receive the intradermal trivalent influenza vaccine containing B strain from the alternate (Victoria) lineage |
| Name | Type | Description |
|---|---|---|
| Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation | BIOLOGICAL | 0.1mL, Intradermal |
| Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal | BIOLOGICAL | 0.1mL, Intradermal |
| Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal | BIOLOGICAL | 0.1mL, Intradermal |
Inclusion Criteria: * Aged 18 through 64 years on the day of inclusion * Informed consent form (ICF) has been signed and dated * Able to attend all scheduled visits and to comply with all trial procedures. Exclusion Criteria: * Subject is pregnant, or lactating, or of childbearing potential (to be ...